Modulation of Immunity by Antiangiogenic Molecules in Cancer
In the last decades a new class of therapeutic drugs have been developed that block tumor angiogenesis. These antiangiogenic molecules, which target VEGF or VEGFR, PDGFR, and c-kit, can act not only on endothelial cells but also on immune cells. Some antiangiogenic molecules inhibit the development...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Clinical and Developmental Immunology |
| Online Access: | http://dx.doi.org/10.1155/2012/492920 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832549095574601728 |
|---|---|
| author | Magali Terme Orianne Colussi Elie Marcheteau Corinne Tanchot Eric Tartour Julien Taieb |
| author_facet | Magali Terme Orianne Colussi Elie Marcheteau Corinne Tanchot Eric Tartour Julien Taieb |
| author_sort | Magali Terme |
| collection | DOAJ |
| description | In the last decades a new class of therapeutic drugs have been developed that block tumor angiogenesis. These antiangiogenic molecules, which target VEGF or VEGFR, PDGFR, and c-kit, can act not only on endothelial cells but also on immune cells. Some antiangiogenic molecules inhibit the development of immunosuppressive mechanisms developed by the tumors to escape the immune system (such as regulatory T cells, myeloid-derived suppressor cells, and immunosuppressive cytokines). These immunomodulatory effects must be characterized in detail to enable a better prescription of these treatments. In this paper we will focus on the impact of anti-angiogenic drugs on immunosuppression and their potential combination with immunotherapeutic strategies. Interestingly, immune parameters or their modulation during treatment could serve as potential biomarkers of response or resistance to anti-angiogenic therapies. |
| format | Article |
| id | doaj-art-68ad833370ab4a6d945d105dc4c2cd99 |
| institution | Kabale University |
| issn | 1740-2522 1740-2530 |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Clinical and Developmental Immunology |
| spelling | doaj-art-68ad833370ab4a6d945d105dc4c2cd992025-02-03T06:12:15ZengWileyClinical and Developmental Immunology1740-25221740-25302012-01-01201210.1155/2012/492920492920Modulation of Immunity by Antiangiogenic Molecules in CancerMagali Terme0Orianne Colussi1Elie Marcheteau2Corinne Tanchot3Eric Tartour4Julien Taieb5INSERM U970, Paris Cardiovascular Research Center (PARCC), Université Paris-Descartes, Sorbonne Paris Cité, 56 rue Leblanc, 75015 Paris, FranceINSERM U970, Paris Cardiovascular Research Center (PARCC), Université Paris-Descartes, Sorbonne Paris Cité, 56 rue Leblanc, 75015 Paris, FranceINSERM U970, Paris Cardiovascular Research Center (PARCC), Université Paris-Descartes, Sorbonne Paris Cité, 56 rue Leblanc, 75015 Paris, FranceINSERM U970, Paris Cardiovascular Research Center (PARCC), Université Paris-Descartes, Sorbonne Paris Cité, 56 rue Leblanc, 75015 Paris, FranceINSERM U970, Paris Cardiovascular Research Center (PARCC), Université Paris-Descartes, Sorbonne Paris Cité, 56 rue Leblanc, 75015 Paris, FranceINSERM U970, Paris Cardiovascular Research Center (PARCC), Université Paris-Descartes, Sorbonne Paris Cité, 56 rue Leblanc, 75015 Paris, FranceIn the last decades a new class of therapeutic drugs have been developed that block tumor angiogenesis. These antiangiogenic molecules, which target VEGF or VEGFR, PDGFR, and c-kit, can act not only on endothelial cells but also on immune cells. Some antiangiogenic molecules inhibit the development of immunosuppressive mechanisms developed by the tumors to escape the immune system (such as regulatory T cells, myeloid-derived suppressor cells, and immunosuppressive cytokines). These immunomodulatory effects must be characterized in detail to enable a better prescription of these treatments. In this paper we will focus on the impact of anti-angiogenic drugs on immunosuppression and their potential combination with immunotherapeutic strategies. Interestingly, immune parameters or their modulation during treatment could serve as potential biomarkers of response or resistance to anti-angiogenic therapies.http://dx.doi.org/10.1155/2012/492920 |
| spellingShingle | Magali Terme Orianne Colussi Elie Marcheteau Corinne Tanchot Eric Tartour Julien Taieb Modulation of Immunity by Antiangiogenic Molecules in Cancer Clinical and Developmental Immunology |
| title | Modulation of Immunity by Antiangiogenic Molecules in Cancer |
| title_full | Modulation of Immunity by Antiangiogenic Molecules in Cancer |
| title_fullStr | Modulation of Immunity by Antiangiogenic Molecules in Cancer |
| title_full_unstemmed | Modulation of Immunity by Antiangiogenic Molecules in Cancer |
| title_short | Modulation of Immunity by Antiangiogenic Molecules in Cancer |
| title_sort | modulation of immunity by antiangiogenic molecules in cancer |
| url | http://dx.doi.org/10.1155/2012/492920 |
| work_keys_str_mv | AT magaliterme modulationofimmunitybyantiangiogenicmoleculesincancer AT oriannecolussi modulationofimmunitybyantiangiogenicmoleculesincancer AT eliemarcheteau modulationofimmunitybyantiangiogenicmoleculesincancer AT corinnetanchot modulationofimmunitybyantiangiogenicmoleculesincancer AT erictartour modulationofimmunitybyantiangiogenicmoleculesincancer AT julientaieb modulationofimmunitybyantiangiogenicmoleculesincancer |